We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $51.36 in the latest trading session, marking a -5.34% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.82% for the day. At the same time, the Dow lost 1.09%, and the tech-heavy Nasdaq lost 2.86%.
Prior to today's trading, shares of the company had lost 2.13% lagged the Medical sector's gain of 5.28% and the S&P 500's gain of 0.71%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.06 per share, which would represent year-over-year growth of 9.4%. Simultaneously, our latest consensus estimate expects the revenue to be $9.95 million, showing a 1017.42% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.44 per share and revenue of $32.45 million, which would represent changes of +31.38% and +824.53%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.59% higher. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 103, positioning it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP - Free Report) closed at $51.36 in the latest trading session, marking a -5.34% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.82% for the day. At the same time, the Dow lost 1.09%, and the tech-heavy Nasdaq lost 2.86%.
Prior to today's trading, shares of the company had lost 2.13% lagged the Medical sector's gain of 5.28% and the S&P 500's gain of 0.71%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.06 per share, which would represent year-over-year growth of 9.4%. Simultaneously, our latest consensus estimate expects the revenue to be $9.95 million, showing a 1017.42% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.44 per share and revenue of $32.45 million, which would represent changes of +31.38% and +824.53%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.59% higher. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 103, positioning it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.